Qc Technologies Inc's Comment on Sales, Marketing and Customers
The company serves customers in energy-intensive computing environments through its laser-based computing business, focusing on applications such as DePin Tokens and AI workloads. It plans to offer qc-LPU100 systems directly to customers and provide access via subscription or usage-based models. The company also seeks to collaborate with potential partners and early adopters for pilot testing and proof-of-concept deployments. Its legacy pharmaceutical business provides therapeutic programs for patients with autoimmune diseases and age-related conditions, including Isomyosamine, which targets autoimmune diseases such as sarcopenia, frailty, rheumatoid arthritis, and inflammatory bowel disease, and Supera-CBD, a synthetic analog of CBD for various conditions.
Q/C Technologies Makes Nasdaq Debut with Strategic Shift into Quantum-Class Computing New York City has long been a hub of financial activity and innovation, and today marks an exciting new chapter for a company at the forefront of technological advancement. Q/C Technologies, Inc. (Nasdaq: QCLS), previously known as TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), has officially begun trading under its new ticker symbol, QCLS. This name change signifies a bold strategic pivot for the company as it enters the groundbreaking field of quantum-class computing.Q/C Technologies transition to its new industry alignment underscores its commitment to revolutionizing computing through the power of light-speed laser technolo...
Qc Technologies Inc’s Comment on Sales, Marketing and Customers
The company serves customers in energy-intensive computing environments through its laser-based computing business, focusing on applications such as DePin Tokens and AI workloads. It plans to offer qc-LPU100 systems directly to customers and provide access via subscription or usage-based models. The company also seeks to collaborate with potential partners and early adopters for pilot testing and proof-of-concept deployments. Its legacy pharmaceutical business provides therapeutic programs for patients with autoimmune diseases and age-related conditions, including Isomyosamine, which targets autoimmune diseases such as sarcopenia, frailty, rheumatoid arthritis, and inflammatory bowel disease, and Supera-CBD, a synthetic analog of CBD for various conditions.
Sources:
Qc Technologies Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Qc Technologies Inc’s corporate clients.
For your research, we’ve provided 9 tables on Qc Technologies Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
